TABLE 2.
Unpublished or ongoing clinical trials of GLP‐1‐based therapies for addictive disorders
| SUD | Study name | Drug | Administration | Estimated patient enrolment | Primary outcome(s) | Expected end date | NCT identifier |
|---|---|---|---|---|---|---|---|
| Alcohol | EXALT | Exenatide | s.c., 2 mg, once weekly | 127 | Reduction in heavy drinking days in patients with AUD, after 26 weeks of treatment | October 2020 | NCT03232112 |
| Alcohol | Exenatide | s.c. single injection, 5 μg | 36 | Alcohol consumption for 4 h in heavy drinkers, alcohol craving for 4 h in heavy drinkers | December 2021 | NCT03645408 | |
| Alcohol/nicotine | GHADD | Exenatide | i.v. dose 0.06 pmol·kg−1·min−1 | 95 | Functional MRI measure of brain activation during cigarette, alcohol and food picture evaluation task. | August 2020 | NCT02690987 |
| Nicotine | DAL | Liraglutide | s.c., 3.0 mg, once daily | 40/80? | 7‐day point prevalence smoking abstinence at 12 weeks, 7‐day point prevalence smoking abstinence at 26 weeks | May 2021 | NCT03712098 |
| Nicotine | SKIP | Dulaglutide | s.c., 1.5 mg, once weekly | 256 | Point prevalence abstinence rate at Week 12 | March 2021 | NCT03204396 |
| Opioids | Liraglutide | s.c., 3.0 mg, once daily | 40 | Change in self‐reported cue‐elicited drug craving, change in ambient drug craving over time | December 2021 | NCT04199728 |
Abbreviations: AUD, alcohol use disorder; GLP‐1, glucagon‐like peptide 1; NCT, National Clinical Trial; SUD, substance use disorder.